US Exchange Filings

Compass Therapeutics Receives Nasdaq Warning Over Minimum Bid Price

Compass Therapeutics has until May 18, 2027, to lift its share price above Nasdaq’s $1 minimum and keep its listing in good standing. The company is weighing options, including a reverse stock split, but has not committed to one.

Compass Therapeutics has received a Nasdaq warning because its share price has remained below the exchange’s $1 minimum for continued listing. The warning does not immediately affect trading: the stock will continue to trade on the Nasdaq Capital Market under the ticker CMPX while the company works to meet the requirement.

  • First deadline: May 18, 2027. Compass has 180 calendar days to regain compliance. It would do so if its closing bid price reaches at least $1 a share for 10 consecutive business days.
  • A possible second period. If the company misses that deadline, it may qualify for another 180 days if it meets Nasdaq’s other applicable listing standards and tells the exchange it intends to address the shortfall, using a reverse stock split if necessary.
  • Delisting remains possible. If Compass does not qualify for the second period or fails to meet the price requirement by its end, its shares could face delisting. The company could appeal a delisting decision, but there is no assurance an appeal would succeed.
  • The company is considering its options. Compass said it will monitor the share price and may consider steps to regain compliance, including a reverse stock split. It did not announce that it would carry out a split.

For now, the issue is the share-price threshold, not an immediate change to the company’s listing or control. A reverse split is one possible way to address the shortfall, but Compass has not committed to that course.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.